Gene Therapy for Bladder Cancer Using Interleukin-2
Author Information
Author(s): Milella M, Jacobelli J, Cavallo F, Guarini A, Velotti F, Frati L, Foà R, Forni G, Santoni A
Primary Institution: Department of Experimental Medicine and Pathology, University of Rome ‘La Sapienza’
Hypothesis
Can interleukin-2 gene transfer enhance the effectiveness of immunotherapy in bladder cancer?
Conclusion
The study suggests that interleukin-2 gene transfer can lead to the rejection of bladder cancer cells in mice, supporting its potential use in gene therapy.
Supporting Evidence
- The engineered bladder cancer cells produced interleukin-2 consistently.
- IL-2 transduced cells showed no changes in growth rate or morphology compared to control cells.
- The engineered cells were rejected by the immune system in mice.
Takeaway
Scientists are trying to help the body fight bladder cancer by making cancer cells produce a special helper called interleukin-2, which helps the immune system work better.
Methodology
The study involved engineering bladder cancer cell lines to produce interleukin-2 and testing their tumorigenicity in mice.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website